A Study of CT-388 in Participants with Obesity or Overweight with At Least One Weight-Related Comorbidity

  • Metabolic Disorder
  • Obesity
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Active, not recruiting

This study runs in
Cities
  • Anaheim
  • Austin
  • Bellaire
  • Birmingham
  • Butte
  • Cedarhurst
  • Cincinnati
  • Clearwater
  • Dallas
  • Fountain Valley
  • Greenville
  • Homewood
  • Knoxville
  • Long Beach
  • Los Angeles
  • Mesa
  • Nashville
  • Northridge
  • Port Orange
  • Rancho Cucamonga
  • Richmond
  • San Antonio
  • St. George
  • Tustin
  • West Hills
Trial Identifier:

NCT06525935 XC45526 CT-388-103

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.

      Carmot Therapeutics, Inc. Sponsor
      Phase 2 Phase
      NCT06525935, CT-388-103, XC45526 Trial Identifier
      CT-388, Placebo Treatments
      Obesity, Overweight Condition
      Official Title

      A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants with Obesity or Overweight with At Least One Weight-Related Comorbidity

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 75 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Male or female, 18 to 75 years of age
      • Body mass index (BMI) ≥30.0 kg/m2, OR BMI ≥27.0 and <30.0 kg/m2 and previously diagnosed with at least 1 of the following weight-related comorbidities, such as: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
      • At least one self-reported unsuccessful effort to lose body weight
      Exclusion Criteria
      • Prior history/diagnosis/lab evidence of any type of diabetes mellitus (e.g., Type 1, Type 2, gestational), or a history of ketoacidosis or hyperosmolar state
      • Self-reported body weight change of >5 kg within 3 months before randomization
      • Any unbalanced/extreme diets within 3 months of the screening visit, or plan to be on such diets during the study
      • Current or recent participation in an organized weight reduction program
      • Current or recent use of any treatment that promotes weight loss or glucose metabolism
      • Current or recent use of treatment that may cause weight gain
      • Prior or planned surgical treatment for obesity
      • Clinically significant or active gastric emptying abnormality, malabsorption, or chronic use of medications that directly affect GI motility
      • History of chronic pancreatitis or acute pancreatitis within 6 months before screening
      • Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
      • History of major depressive disorder within 2 years of screening, or any history/diagnosis of other severe psychiatric conditions (Note: Prospective participants with depression or anxiety whose disease state, in the opinion of the Investigator, is considered stable and expected to remain stable throughout the course of the study, may be considered for inclusion)
      • Family or personal history of medullary thyroid carcinoma
      • Serum calcitonin ≥ 20 ng/L
      • Women who are pregnant, breastfeeding, or intend to become pregnant, or are of childbearing potential and not using a highly effective contraceptive method

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Obesity

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now